China’s State Administration for Market Regulation (“SAMR”) recently issued proposed Measures on Supervision and Administration of Entrusted Manufacturing for Food (the “Proposed Measures”). The Proposed Measures expand the rights and obligations of companies that entrust food manufacturing to a licensed food producer in China. Consistent with other recent rules, such as the Administrative Measures for the Inspection and Supervision of Food Manufacturing and Distribution, the Proposed Measures build out the body of implementing rules under the Food Safety Law governing the food manufacturing process.

Of note, the Proposed Measures make it clear that any ex-China company must establish a Chinese entity to contract with a licensed food manufacturer in China to produce food for sale in China, and the ex-China company’s Chinese entity must obtain a food distribution license, other distribution credentials, or a food manufacturing license before that entity can contract with a licensed food manufacturer for these purposes. This requirement does not apply when a manufacturer is being entrusted by the ex-China company to manufacture food for export only. In that case, the ex-China company can contract directly with the entrusted local entity.

The Proposed Measures contain additional limitations on the permitted scope of contract manufacturing. Under the Proposed Measures, only an entity that holds a health food registration and a health food manufacturing or distribution license can entrust another party to manufacture the health food. Furthermore, the contract manufacturer must cover all stages of the health food production; in other words, the Proposed Measures prohibit a health food registrant from separating different stages of production and contracting with different parties for different stages of the production of the health food. The Proposed Measures also prohibit contract manufacturing of “food formulated for special medical purposes” and powdered infant formula produced within China.

The Proposed Measures provide for the obligations of the entrusting party and the entrusted party, including the obligation of the entrusting party to oversee production. The Proposed Measures require that these parties enter into a contract to govern the relationship and set forth specific items that the contract must contain. Further, this arrangement needs to be reported to the county-level food safety supervision and administration department. The Proposed Measures also make the inspection of contract manufacturers an inspection priority for local food safety supervision and administration departments. Specifically, under the Proposed Measures, the licenses of both the entrusting party and the entrusted party, the record of the entrusting party’s oversight of the production, and the food labeling, among others, are to be inspected.

The comment period on the Proposed Measures is currently closed. However, food companies should closely follow any further development of the Proposed Measures.

For further information or inquiries relating to this post, please email APACRegBlog@cov.com.

Contributors for the China & APAC Food, Drug, Device, and Cosmetics blog:

John Balzano, Julia Post, Muyun Hu, Kaixin Fan, and Kexin Yang.

Photo of Kaixin Fan Kaixin Fan

Kaixin Fan is a member of the Food, Drug, and Device Practice Group. She advises pharmaceutical, biotechnology, and medical device companies as well as trade associations in regulatory matters. She has experience in matters relating to FDA informed consent requirements, advertising and promotion…

Kaixin Fan is a member of the Food, Drug, and Device Practice Group. She advises pharmaceutical, biotechnology, and medical device companies as well as trade associations in regulatory matters. She has experience in matters relating to FDA informed consent requirements, advertising and promotion issues, and other aspects of U.S. federal and state regulation of pharmaceuticals, biologics, and medical devices. Kaixin also assists clients in navigating complex regulatory matters in China, and works closely with local counsel in other Asia-Pacific jurisdictions. She has supported life science transactions by evaluating regulatory compliance of companies and advising on commercial agreements.

Kaixin maintains an active pro bono practice, with experience in the areas of housing, reproductive rights, and gender-based violence.

Photo of John Balzano John Balzano

John Balzano represents companies and business associations on U.S. and China regulatory and policy matters related to food, drugs, medical devices, cosmetics, and other regulated products.

John has over a decade of experience with legal and regulatory issues related to China, particularly with…

John Balzano represents companies and business associations on U.S. and China regulatory and policy matters related to food, drugs, medical devices, cosmetics, and other regulated products.

John has over a decade of experience with legal and regulatory issues related to China, particularly with regard to products regulated by the State Administration for Market Regulation, the National Medical Products Administration (NMPA), and other agriculture, animal and healthcare (including digital health) products and services. He assists clients with developing strategies to obtain pre-market approvals for these products in China, including clinical development, understanding relevant pricing and reimbursement policies, and reviewing distribution and promotional plans.

He also advises on regulatory compliance, due diligence, and enforcement matters for China operations, including drafting and revising and integrating China and global standard operating procedures, assessing the functions of regulatory departments in China, responding to inspection results and enforcement inquiries, and implementing product recalls. John also has significant experience designing strategies to handle professional consumer litigation for food and cosmetic companies operating in China and working with local counsel.

He advises companies and industry associations on their advocacy strategies, including the notice and comment process before NMPA and other regulatory agencies.

John has particular experience in the U.S. advising on the requirements for the acquisition and transfer of biospecimens for research purposes.

Photo of Julia Post Julia Post

Julia Post advises companies and trade associations on a broad range of regulatory and policy matters related to drugs, biologics, and other regulated products in both the U.S. and China. Julia has significant experience in advising clients on clinical trial and product development…

Julia Post advises companies and trade associations on a broad range of regulatory and policy matters related to drugs, biologics, and other regulated products in both the U.S. and China. Julia has significant experience in advising clients on clinical trial and product development matters, including informed consent requirements, biospecimen procurement and research use, and other good clinical practice. She advises clients regularly on product life-cycle management issues, including patent linkage frameworks and marketing exclusivity in the U.S. and China.

Julia works with pharmaceutical, medical device, food, and cosmetics clients on complex regulatory compliance matters and helps them develop their advocacy strategies before U.S. and China regulators, at both national and local levels. She regularly assists companies and trade associations on policy issues, including the development and submission of comments on legislative and regulatory proposals. Julia works closely with local counsel throughout the Asia-Pacific region to assist clients with their marketing approval and compliance strategies.

Prior to joining the Food, Drug, and Device practice group, Julia was a member of the Litigation practice group where she focused on representing clients in Hatch-Waxman patent litigation.

Julia has an active pro bono practice at Covington, with a particular focus on reproductive justice matters and representation of third-party caregivers and children in custody cases.